← Leaderboards
Elizabeth Connick
University Of Colorado Denver
$17,363,459
Attributed
$24,395,548
Total exposure
35
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2005–24$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$24,395,548 · 35
By mechanism
R01$12,059,881 · 4
P01$8,103,421 · 1
M01$2,045,473 · 24
R56$903,747 · 2
R21$700,099 · 2
R29$316,488 · 1
Top collaborators
- Christopher A Desouza8 shared
- Pamela J Skinner8 shared
- Michael A Grandner6 shared
- Freda Patterson6 shared
- Sara Gianella Weibel1 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Robert Turner Schooley$73,100,957
- Thomas A Campbell$2,616,890
- John G. Gerber$1,597,914
- Jennifer Justice Kiser$3,749,896
- Henry Milgrom$3,401
Others in their field
Top investigators on “Hiv Infections”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
- Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
- Judith S. Currier · University Of California Los Angeles$466,447,923
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
Research focus
Hiv InfectionsInfectionClinical ResearchHuman SubjectVirusHiv-1United States National Institutes Of HealthAids TherapyAcuteRitonavirVirus ReplicationPhenotypeHuman Therapy EvaluationInsightCellsMediatingAdultRisk FactorsCardiovascular DiseasesChronicCardiovascular Disorder RiskMorbidity - Disease RateIn VivoPrograms
Grant awards (71)
Immune Microenvironments That Impact HIV Persistence and Expression During ART$153,311
R56 · FY2024 · AI · contact PI
Using Sleep Health to Optimize Smoking Cessation Treatment Response in HIV-Positive Adults$764,472
R01 · FY2023 · DA · contact PI
Using Sleep Health to Optimize Smoking Cessation Treatment Response in HIV-Positive Adults$109,026
R01 · FY2023 · DA · contact PI
Using Sleep Health to Optimize Smoking Cessation Treatment Response in HIV-Positive Adults$766,569
R01 · FY2022 · DA · contact PI
Using Sleep Health to Optimize Smoking Cessation Treatment Response in HIV-Positive Adults$109,026
R01 · FY2022 · DA · contact PI
Using Sleep Health to Optimize Smoking Cessation Treatment Response in HIV-Positive Adults$768,604
R01 · FY2021 · DA · contact PI
Using Sleep Health to Optimize Smoking Cessation Treatment Response in HIV-Positive Adults$783,956
R01 · FY2020 · DA · contact PI
HIV-1, Insufficient Sleep and Vascular Endothelial Dysfunction$726,300
R01 · FY2019 · HL
HIV-1, Insufficient Sleep and Vascular Endothelial Dysfunction$739,390
R01 · FY2018 · HL
HIV-1, Insufficient Sleep and Vascular Endothelial Dysfunction$750,170
R01 · FY2017 · HL
Mechanisms Underlying Persistent Lentivirus Replication in Follicular T Cells$719,925
R01 · FY2017 · AI · contact PI
Mechanisms Underlying Persistent Lentivirus Replication in Follicular T Cells$341,106
R01 · FY2017 · AI · contact PI
HIV-1, Insufficient Sleep and Vascular Endothelial Dysfunction$790,365
R01 · FY2016 · HL
Mechanisms Underlying Persistent Lentivirus Replication in Follicular T Cells$489,622
R01 · FY2016 · AI · contact PI
Mechanisms Underlying Persistent Lentivirus Replication in Follicular T Cells$341,749
R01 · FY2016 · AI · contact PI
Mechanisms Underlying Persistent Lentivirus Replication in Follicular T Cells$845,761
R01 · FY2015 · AI · contact PI
Mechanisms Underlying Persistent Lentivirus Replication in Follicular T Cells$716,691
R01 · FY2014 · AI · contact PI
HIV-1, Exercise and Endothelial Function$397,019
R01 · FY2014 · HL
Mechanisms Underlying Persistent Lentivirus Replication in Follicular T Cells$699,086
R01 · FY2013 · AI · contact PI
HIV-1, Exercise and Endothelial Function$386,521
R01 · FY2013 · HL
HIV-1, Exercise and Endothelial Function$413,393
R01 · FY2012 · HL
HIV-1, Exercise and Endothelial Function$401,130
R01 · FY2011 · HL
CTL Exclusion from Lymphoid Follicles as a Mechanism of Lentivirus Immune Invasio$750,436
R56 · FY2010 · AI
Sex Differences in Plasma HIV-1 RNA Concentrations$174,083
R21 · FY2010 · HD · contact PI
Immunology Core$266,439
P30 · FY2008 · AI · contact PI
ACUTE HIV INFECTION AND EARLY DISEASE RESEARCH PROGRAM (AIEDRP) CORE01 DATA PROT$58,031
M01 · FY2008 · RR · contact PI
TRTMNT W/TENOFOVIR DF,EMTRICITABINE,& LOPINAVIR/RITONAVIR VS NO THERAPY IN HIV$4,145
M01 · FY2008 · RR · contact PI
TRTMNT W/LAMIVUDINE+STAVUDINE+ABACAVIR+AMPRENAVIR/RITONAVIR W/SUPV INTERRUPTION$1,951
M01 · FY2008 · RR · contact PI
ACTG A5201(V 20)-REGMIN SMPLFCTN TO ATAZANAVIR/RITONAVIR AFTR VRLGC SUPPRESSION$1,463
M01 · FY2008 · RR · contact PI
TRTMNT INTRUPTN AMNG SBJTS ON POTENT ANTIRTROVIRAL THRPY W/IN 16 DYS OF DIAGNSS$488
M01 · FY2008 · RR · contact PI
Immunopathogenesis of Acute HIV-1 Infection$2,087,864
P01 · FY2007 · AI · contact PI
ACUTE HIV INFECTION AND EARLY DISEASE RESEARCH PROGRAM (AIEDRP) CORE01 DATA PROT$294,118
M01 · FY2007 · RR · contact PI
Sex Differences in Plasma HIV-1 RNA Concentrations$172,023
R21 · FY2007 · HD · contact PI
TRTMNT W/TENOFOVIR DF,EMTRICITABINE,& LOPINAVIR/RITONAVIR VS NO THERAPY IN HIV$21,010
M01 · FY2007 · RR · contact PI
TRTMNT W/LAMIVUDINE+STAVUDINE+ABACAVIR+AMPRENAVIR/RITONAVIR W/SUPV INTERRUPTION$9,888
M01 · FY2007 · RR · contact PI
ACTG A5201(V 20)-REGMIN SMPLFCTN TO ATAZANAVIR/RITONAVIR AFTR VRLGC SUPPRESSION$7,415
M01 · FY2007 · RR · contact PI
TRTMNT INTRUPTN AMNG SBJTS ON POTENT ANTIRTROVIRAL THRPY W/IN 16 DYS OF DIAGNSS$2,473
M01 · FY2007 · RR · contact PI
Immunopathogenesis of Acute HIV-1 Infection$2,028,889
P01 · FY2006 · AI · contact PI
ACUTE HIV INFECTION AND EARLY DISEASE RESEARCH PROGRAM (AIEDRP) CORE01 DATA PROT$277,860
M01 · FY2006 · RR · contact PI
Sex Differences in Plasma HIV-1 RNA Concentrations$201,493
R21 · FY2006 · HD · contact PI
ACTG A5201(V 20)-REGMIN SMPLFCTN TO ATAZANAVIR/RITONAVIR AFTR VRLGC SUPPRESSION$103,285
M01 · FY2006 · RR · contact PI
TRTMNT W/LAMIVUDINE+STAVUDINE+ABACAVIR+AMPRENAVIR/RITONAVIR W/SUPV INTERRUPTION$48,444
M01 · FY2006 · RR · contact PI
TRTMNT W/TENOFOVIR DF,EMTRICITABINE,& LOPINAVIR/RITONAVIR VS NO THERAPY IN HIV$22,850
M01 · FY2006 · RR · contact PI
Immunopathogenesis of Acute HIV-1 Infection$2,020,340
P01 · FY2005 · AI
TRTMNT W/LAMIVUDINE+STAVUDINE+ABACAVIR+AMPRENAVIR/RITONAVIR W/SUPV INTERRUPTION$79,256
M01 · FY2005 · RR
ACUTE HIV INFECTION AND EARLY DISEASE RESEARCH PROGRAM (AIEDRP) CORE01 DATA PROT$69,118
M01 · FY2005 · RR
IMMUNE RECONSTITUTION W/GROWTH HORMIN HIV SUBJW/INCOMPCD4+LYMPHRESTON HAART$48,844
M01 · FY2005 · RR
ACTG A5201(V 20)-REGMIN SMPLFCTN TO ATAZANAVIR/RITONAVIR AFTR VRLGC SUPPRESSION$21,197
M01 · FY2005 · RR
ACTG A5015-IMMUNOLOGIC &VIROLOGIC INDICES ASSOC W/ AGING IN HIV-INFECTED SUBJEC$4,609
M01 · FY2005 · RR
Immunopathogenesis of Acute HIV-1 Infection$1,966,328
P01 · FY2004 · AI
Tx w/ Lamivudine+Stavudine+Abacavir+Amprenavir+Ritonavir$72,488
M01 · FY2004 · RR
Evaluate Ability of Vaccine-Induced Helper &CTL$13,424
M01 · FY2004 · RR
IMMUNE RECONSTITUTION W/ GROWTH HORMONE IN HIV$13,424
M01 · FY2004 · RR
ACTG A5136-Immune Effect of Antiretroviral Tx Intensity$7,384
M01 · FY2004 · RR
ACTG A5015-Immunologic &Virologic Indices Assoc w/Aging$2,684
M01 · FY2004 · RR
CD8+TCell Antiretroviral Mechanisms in Lymphoid Tissue$152,500
R21 · FY2003 · AI
ACTG 375 IMMUNOLOGIC &VIROLOGIC CONSEQUENCES--LONG TERM HAART IN HIV-1 DISE$190,747
M01 · FY2002 · RR
ACTG328 RECOMBINANT HUMAN INTERLEUKIN 2--IV OR SUBCUTANEOUS ADMINISTRATION$190,747
M01 · FY2002 · RR
COSTIMULATORY MOLECULES, CTL, AND HIV IN LYMPHOID TISSUE$105,700
R29 · FY2002 · AI
ACTG328 RECOMBINANT HUMAN INTERLEUKIN 2--IV OR SUBCUTANEOUS ADMINISTRATION$190,747
M01 · FY2001 · RR
ACTG 375 IMMUNOLOGIC &VIROLOGIC CONSEQUENCES--LONG TERM HAART IN HIV-1 DISE$190,747
M01 · FY2001 · RR
COSTIMULATORY MOLECULES, CTL, AND HIV IN LYMPHOID TISSUE$105,700
R29 · FY2001 · AI
ACTG328 RECOMBINANT HUMAN INTERLEUKIN 2--IV OR SUBCUTANEOUS ADMINISTRATION$0
M01 · FY2001 · RR
ACTG 375 IMMUNOLOGIC &VIROLOGIC CONSEQUENCES--LONG TERM HAART IN HIV-1 DISE$0
M01 · FY2001 · RR
COSTIMULATORY MOLECULES, CTL, AND HIV IN LYMPHOID TISSUE$105,088
R29 · FY2000 · AI
AUTOLOGOUS CD4-ZETA GENE-MODIFIED T CELLS IN HIV INFECTED PATIENTS$32,212
M01 · FY2000 · RR
ACTG 375 IMMUNOLOGIC &VIROLOGIC CONSEQUENCES--LONG TERM HAART IN HIV-1 DISE$32,212
M01 · FY2000 · RR
ACTG328 RECOMBINANT HUMAN INTERLEUKIN 2--IV OR SUBCUTANEOUS ADMINISTRATION$32,212
M01 · FY2000 · RR
AUTOLOGOUS CD4-ZETA GENE-MODIFIED T CELLS IN HIV INFECTED PATIENTS$0
M01 · FY2000 · RR
ACTG328 RECOMBINANT HUMAN INTERLEUKIN 2--IV OR SUBCUTANEOUS ADMINISTRATION$0
M01 · FY2000 · RR
ACTG 375 IMMUNOLOGIC &VIROLOGIC CONSEQUENCES--LONG TERM HAART IN HIV-1 DISE$0
M01 · FY2000 · RR